Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation
In this MAIC, sotorasib and adagrasib showed comparable efficacy in previously treated advanced KRAS G12C-mutated NSCLC. Among patients with baseline brain metastases, PFS point estimates favored sotorasib. Sotorasib also demonstrated a favorable overall safety profile. These findings may help inform payer decisions and clinical practice in the treatment of KRAS G12C-mutated NSCLC.
Authors
- Noor Khairiah A. Karim (ORCID: https://orcid.org/0000-0001-8176-3939)
- Jürgen Wolf (ORCID: https://orcid.org/0000-0002-3869-4736)
- Divyan Chopra (ORCID: https://orcid.org/0000-0003-1375-5413)
- Cynthia Obiozor
- Björn Stollenwerk (ORCID: https://orcid.org/0000-0002-3189-409X)
- David Michael Waterhouse (ORCID: https://orcid.org/0000-0001-5589-9939)
- Zhiyi Lan (ORCID: https://orcid.org/0000-0001-5519-2474)
- Hoora Moradian
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
Institutions
- Hebron University (PS)
- Amgen (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- Amgen (Switzerland) (CH)
- Centrum für Integrierte Onkologie (DE)
- Oncology Hematology Care (US)
- Brunel University of London (GB)
- Cytel (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1007/s12325-025-03259-8
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Amgen
- AstraZeneca